Education
About Us
Working with TipRanks
Follow Us
Assembly Biosciences (ASMB)
NASDAQ:ASMB
ASMB Stock Chart & Stats
$29.91
-$0.45(-2.59%)
At close: 4:00 PM EST
$29.91
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$7.75 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$506.78M
Enterprise Value$66.63M
Total Cash (Recent Filing)$232.56M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 05, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding15,817,140
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.84
Price to Sales (P/S)3.32
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.13
Enterprise Value/Revenue1.79
Enterprise Value/Gross Profit9.82
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$43.00Price Target Upside43.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementInterim Phase 1b results demonstrated potent antiviral activity and near-complete reductions in viral shedding, supporting planned Phase 2 initiation in mid-2026 and reinforcing best-in-class potential for a long-acting oral HSV therapy.
Financial RunwayReported cash runway into late 2027 provides financial visibility to progress multiple antiviral programs through key 2026 development milestones without immediate financing pressure.
Market OpportunityA once-monthly oral HSV treatment that improves on daily generics could address unmet patient demand and support an approximately $1 billion U.S. market opportunity, offering significant commercial upside.
Bears Say
Capital Needs And Commercial AdoptionRequirement for additional capital to fund late-stage trials raises dilution risk, while uncertain physician and patient adoption of a new dosing regimen could reduce projected peak revenues.
Partner Dependence And Opt-in RiskDependence on a single large partner and its opt-in decision creates concentration risk that could limit upside or alter development plans if the partner changes strategy.
Regulatory And Manufacturing DelaysManufacturing complexity or regulatory review delays for novel long-acting oral formulations could extend timelines and raise program costs, pressuring valuation.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $7.75 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $506.78M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Mar 05, 2026 which is in 47 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on Nov 10, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.821 by $0.101.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.86.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 15,817,140 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.821. Following the earnings report the stock price went up 3.305%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (43.76% Upside)
$43.00 (43.76% Upside)
Hedge Fund Trend
Increased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.3%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-36.94%
Trailing 12-Months
Asset Growth
-29.95%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$43.00
▲(43.76% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
29.34% Insiders
3.94% Mutual Funds
60.21% Other Institutional Investors
3.61% Public Companies and
Individual Investors